Are DEA-waivered Buprenorphine Prescribers Co-located With Behavioral Health Clinicians?

Medication is increasingly used to treat opioid use disorder (OUD) in primary care. It incorporates medication (ie, buprenorphine) with behavioral therapy and/or psychosocial services. Targeted planning for co-location of DEA-waivered buprenorphine prescribers and behavioral health (BH) clinicians could increase the use of MOUD. Presently, less than half of all waivered prescribers, outside of hospitals, are co-located with BH clinicians.

This brief provides information on where co-location of DEA-waivered buprenorphine prescribers and BH clinicians occurs and among which type of providers. As this brief details, co-location varies geographically and by profession.

January 3, 2023
Array, Array, Array, Array, Array

January 3, 2023

    Want to stay up to date?

    Sign up for our mailing and never miss a new piece of information.

    I would like updates for:

    Filter Results


    Filter Search Results